WD Rutherford LLC Sells 255 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

WD Rutherford LLC lessened its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.5% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 7,011 shares of the medical research company’s stock after selling 255 shares during the period. Thermo Fisher Scientific makes up about 1.8% of WD Rutherford LLC’s investment portfolio, making the stock its 27th biggest holding. WD Rutherford LLC’s holdings in Thermo Fisher Scientific were worth $3,489,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Bernard Wealth Management Corp. acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth $25,000. FPC Investment Advisory Inc. acquired a new position in shares of Thermo Fisher Scientific during the fourth quarter worth about $28,000. Pillar Financial Advisors LLC acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at approximately $29,000. Ameriflex Group Inc. bought a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth $30,000. Finally, Noble Wealth Management PBC bought a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at about $35,000. 89.23% of the stock is owned by institutional investors.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the transaction, the executive vice president now owns 23,167 shares in the company, valued at $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Stock Performance

Shares of NYSE:TMO opened at $405.15 on Tuesday. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a 12-month low of $390.50 and a 12-month high of $627.88. The company’s 50 day moving average price is $416.55 and its two-hundred day moving average price is $491.11. The firm has a market cap of $152.94 billion, a PE ratio of 24.51, a PEG ratio of 2.99 and a beta of 0.78.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The firm had revenue of $10.36 billion during the quarter, compared to analysts’ expectations of $10.23 billion. During the same period in the previous year, the firm earned $5.11 EPS. The company’s quarterly revenue was up .2% compared to the same quarter last year. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 annualized dividend and a dividend yield of 0.42%. Thermo Fisher Scientific’s dividend payout ratio is 10.09%.

Analysts Set New Price Targets

TMO has been the topic of a number of analyst reports. Stifel Nicolaus dropped their price objective on Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating on the stock in a research note on Thursday, April 24th. Scotiabank cut their price target on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a “sector perform” rating for the company in a research note on Friday, April 25th. Wells Fargo & Company lowered their price objective on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an “overweight” rating on the stock in a research note on Thursday, April 24th. Barclays reduced their price target on Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating for the company in a report on Thursday, April 10th. Finally, Robert W. Baird cut their price objective on Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating for the company in a research report on Thursday, April 24th. Four equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $605.30.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.